AbbVie says that Elahere is the first and only folate receptor alpha (FRÉ‘)-directed antibody drug conjugate (ADC) medicine ...
Aldeyra Therapeutics (NASDAQ:ALDX) announced FDA acceptance of its resubmitted market application for topical ocular ...
AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
Revuforj is Syndax's second first-in-class approval for 2024, coming after the company and partner Incyte got a green light ...
Upon exercise of the option, AbbVie would pay Aldeyra a $100 million upfront cash payment, less previously paid option fees of $6 million. In addition, Aldeyra would be eligible to receive up to $300 ...
Upon exercise of the option, AbbVie would pay Aldeyra a $100M upfront cash payment, less previously paid option fees of $6M. In addition, Aldeyra would be eligible to receive up to $300 million in ...
Headlines,AbbVie Increases Dividend Payment for 2024,Company’s Strong Cash Flow Ensures Sustainability of Dividend,AbbVie’s ...
Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ...
Patent expirations from Brukinsa’s existing competitors may bring biosimilar drugs into the field before Brukinsa reaches its full commercial potential. BeiGene may lose the lawsuit to AbbVie over ...
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
As a leading provider of direct-to-patient and direct-to-physician marketing solutions, Health Monitor Network is once again expanding its senior leadership team during this period of strong growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback